WeVote
Log In

Bill

Bill

AB 575

Relating to: prohibiting state agencies and local governmental units from using facial recognition technology or data generated from it.

2025-2026 Regular Session Introduced by Ryan Clancy and 7 co-sponsors

Requires most California health plans to cover at least one FDA-approved anti-obesity medication and intensive behavioral therapy without prior authorization, effective 1/1/2026.

Read first time and referred to Committee on Criminal Justice and Public Safety
0
WeVote Research Nonpartisan
Bill Summary · AB 575

AB 575 — Obesity Prevention Treatment Parity Act (Arambula)

Status: In committee; first hearing set then canceled at author's request. Introduced: February 12, 2025.

Purpose / Intent

AB 575 seeks to expand insurance coverage for evidence-based obesity treatments and reduce barriers to care by requiring most individual and group health plans and insurance policies that cover outpatient prescription drugs to also cover (without prior authorization) at least one FDA‑approved anti‑obesity medication and intensive behavioral therapy for obesity. The Legislature describes obesity as a chronic disease with major health and economic impacts and cites equity concerns in access to treatment.

Key provisions

  • Effective date: applies to group or individual health care service plan contracts and health insurance policies issued, amended, or renewed on or after January 1, 2026.
  • Mandatory coverage (without prior authorization) for:
    • At least one FDA‑approved anti‑obesity medication (explicitly including, but not limited to, GLP‑1 receptor agonists — GLP‑1RAs); and
    • Intensive behavioral therapy for the treatment of obesity.
  • Limits on utilization management:
    • Plans/insurers may apply utilization management to determine medical necessity, but only if those determinations are made in the same manner as for any other covered illness/condition.
    • Coverage criteria for FDA‑approved anti‑obesity medications shall not be more restrictive than the FDA‑approved indications for those drugs.
  • Exceptions:
    • Does not apply to specialized plans that cover only dental or vision benefits, or to Medicare supplement (“Medigap”) contracts.
  • Definitions:
    • “FDA‑approved anti‑obesity medication” = medication with an FDA indication for chronic weight management in patients with obesity.
    • “GLP‑1RAs” = class of drugs that lower blood sugar and promote weight loss.

Who is affected

  • Affected: Californians enrolled in individual or group plans/policies that provide outpatient prescription drug benefits (regulated by the Department of Managed Health Care and the Department of Insurance), and the issuing insurers/plans.
  • Not affected: plans without outpatient drug benefits, dental or vision‑only plans, Medigap policies, and contracts not issued/amended/renewed on/after 1/1/2026 (i.e., existing coverage persists until renewal).

Fiscal and legal notes

  • The bill adds Section 1374.6 to the Health and Safety Code and Section 10123.62 to the Insurance Code.
  • Because Knox‑Keene provisions make willful violations criminal, the bill is identified as imposing a state‑mandated local program; however, the bill states no state reimbursement is required for a specified reason.
  • Digest indicators: No appropriation; fiscal committee review required.

Legislative timeline (selected)

  • 2025-02-12: Read first time; to print.
  • 2025-02-24: Referred to Assembly Committee on Health.
  • 2025-03-12 to 03-13: Amended and re-referred to Health Committee.
  • 2025-04-28: Committee hearing set; hearing canceled at author’s request.

Potential impacts (summary)

  • Increased access to GLP‑1RAs and behavioral therapy for obesity, potentially improving health outcomes and addressing equity gaps.
  • Possible upward pressure on plan drug costs and premiums; insurers retain standard medical‑necessity review tools but cannot impose prior authorization for the specified treatments.
  • Transition timing tied to contract issuance/amendment/renewal on or after Jan 1, 2026.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.